<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04088292</url>
  </required_header>
  <id_info>
    <org_study_id>STRATIFY-1</org_study_id>
    <nct_id>NCT04088292</nct_id>
  </id_info>
  <brief_title>Low Dose Thrombolysis, Ultrasound Assisted Thrombolysis or Heparin for Intermediate High Risk Pulmonary Embolism</brief_title>
  <acronym>STRATIFY</acronym>
  <official_title>Low Dose Thrombolysis, Ultrasound Assisted Thrombolysis or Heparin for Intermediate High Risk Pulmonary Embolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Herlev and Gentofte Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Bispebjerg and Frederiksberg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hillerod Hospital, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Copenhagen University Hospital, Hvidovre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open label clinical randomized trial comparing three strategies for managing acute&#xD;
      intermediate-high risk pulmonary embolism&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Trial acronym: STRATIFY Background: Intermediate-high risk pulmonary embolism (PE) is&#xD;
      associated with a significant risk of death or hemodynamic deterioration. The optimal&#xD;
      treatment strategy should balance efficacy in reducing thrombus burden and hemodynamic&#xD;
      compromise with risk of complications, in particular bleeding. Previous studies have&#xD;
      investigated conventional high-dose, short term thrombolysis by (rtPA), finding a reduction&#xD;
      in risk hemodynamic deterioration, but no reduction in mortality and a substantial increase&#xD;
      in significant bleeding complications.&#xD;
&#xD;
      Catheter based techniques and low dose thrombolysis may offer lower risk of complication with&#xD;
      reasonable efficacy. Such studies have not been performed in RCTs with a reasonable sample&#xD;
      size, and no study have compared low dose intravenous thrombolysis and catheter based&#xD;
      techniques.&#xD;
&#xD;
      The current trial addresses this paucity of data by randomizing patients to one of three&#xD;
      treatment modalities:&#xD;
&#xD;
      Intervention: 1:1:1 randomization, stratified for site to&#xD;
&#xD;
        -  UltraSound Assisted Thrombolysis (USAT) with low dose thrombolysis (20 mg of rtPA,&#xD;
           Alteplase) over 6 hours plus unfractionated heparin (UFH) or low molecular weight&#xD;
           heparin (LMWH) within 12 hours of randomization&#xD;
&#xD;
        -  Intravenous low dose thrombolysis (20 mg of rtPA, Alteplase) over 6 hours plus UFH or&#xD;
           low molecular weight heparin (LMWH).&#xD;
&#xD;
        -  UFH or low molecular weight heparin (LMWH) only (with option for conventional&#xD;
           thrombolysis according to local protocols for hemodynamic deterioration) Design:&#xD;
           Regional collaborative, randomized trial with 1:1:1 allocation of 210 patients with&#xD;
           acute intermediate-high risk PE with no absolute contraindications to thrombolysis&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">June 6, 2019</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 5, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized clinical trial with 1:1:1 allocation to treatment strata</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Primary endpoint will be assessed by assessor blinded to the intervention</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in Miller score comparing low dose thrombolysis and heparin alone groups</measure>
    <time_frame>at 48 to 96 hours post randomization</time_frame>
    <description>Reduction in Miller Score and on follow-up (48-96 h) CT pulmonary Angiography comparing low-dose rtPA (±USAT) to UFH/LMWH group (p&lt;0.01, N=210)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduction i Miller score comparing low dose thrombolysis by iv and by USATgroups</measure>
    <time_frame>at 48 to 96 hours post randomization</time_frame>
    <description>reduction in Miller Score and on follow-up (48-96 h) CT pulmonary Angiography comparing low-dose rtPA by USAT to iv, p&lt;0.04, N=140)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of bleeding complications</measure>
    <time_frame>Until hospital discharge, on average 1 week</time_frame>
    <description>Bleeding complications (major and minor bleeding complication according the TIMI classification)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay of index admission</measure>
    <time_frame>End of study, expected to be 2 years</time_frame>
    <description>Duration of index admission, including hospital based rehabilitation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnea index by visual analogue scale</measure>
    <time_frame>End of study, expected to be 2 years</time_frame>
    <description>Dyspnea index (Visual analog scale) after 48-96 h and after 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in oxygen supplement (FiO2)</measure>
    <time_frame>at 48 to 96 hours post randomization</time_frame>
    <description>FiO2 (in %)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>End of study, expected to be 2 years</time_frame>
    <description>Mortality in the three groups (log-rank), and hazard ratio in multivariable analysis using the UFH/LMWH as reference</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in D-dimer values</measure>
    <time_frame>at 48 to 96 hours post randomization</time_frame>
    <description>Reduction in D-dimer from baseline to 48-96h post randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Pulmonary Hypertension</measure>
    <time_frame>3 months follow-up</time_frame>
    <description>Incidence of TR gradient &gt; 40 mmHg at 3 months follow-up echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in troponin levels</measure>
    <time_frame>at 48 to 96 hours post randomization</time_frame>
    <description>Relative reduction in TnI/T from baseline to 48-96 h post intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in NT-pro-BNP levels</measure>
    <time_frame>3 months follow-up</time_frame>
    <description>Reduction in NT-pro-BNP at 48-96 hours and 3 months</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Pulmonary Embolism</condition>
  <arm_group>
    <arm_group_label>USAT + low dose thrombolysis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>UltraSound Assisted Thrombolysis (USAT) with low dose thrombolysis (20 mg of rtPA, Alteplase) over 6 hours plus unfractionated heparin (UFH) or low molecular weight heparin (LMWH) within 12 hours of randomization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose thrombolysis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous low dose thrombolysis (20 mg of rtPA, Alteplase) over 6 hours plus UFH or low molecular weight heparin (LMWH).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heparin alone</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>UFH or low molecular weight heparin (LMWH) only (with option for conventional thrombolysis according to local protocols for hemodynamic deterioration)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alteplase 20 Mg Powder for Solution for Injection Vial</intervention_name>
    <description>Low dose alteplase delivered IV or bu Ultrasound Assisted Thrombolysis device</description>
    <arm_group_label>Low dose thrombolysis</arm_group_label>
    <arm_group_label>USAT + low dose thrombolysis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ultrasound assisted Thrombolysis</intervention_name>
    <description>Ultrasound assisted thrombolysis (USAT)</description>
    <arm_group_label>USAT + low dose thrombolysis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years&#xD;
&#xD;
          2. Informed consent for trial participation&#xD;
&#xD;
          3. Intermediate high-risk PE according to ESC criteria&#xD;
&#xD;
          4. Thrombus visible in main, lobar or segmental pulmonary arteries on CT angiography&#xD;
&#xD;
          5. 14 days of symptoms or less&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Altered mental state (GCS &lt; 14)&#xD;
&#xD;
          2. No qualifying CT angiography performed (&gt; 24 hour since CT angiography)&#xD;
&#xD;
          3. Females of child bearing potential, unless negative HCG test is present&#xD;
&#xD;
          4. Thrombolysis for PE within 14 days of randomization&#xD;
&#xD;
          5. Thrombus passing through patent Foramen Ovale (risk of paradoxical embolism)&#xD;
&#xD;
          6. Ongoing oral anticoagulation therapy (heparins, aspirin, antiplatelet therapy and NOAC&#xD;
             allowed)&#xD;
&#xD;
          7. Comorbidity making 6 months survival unlikely&#xD;
&#xD;
          8. Absolute contraindications for thrombolysis&#xD;
&#xD;
               1. Hemorrhagic stroke or stroke of unknown origin at any time&#xD;
&#xD;
               2. Ischemic stroke in the preceding 6 months&#xD;
&#xD;
               3. Central nervous system damage or neoplasms&#xD;
&#xD;
               4. Recent major trauma/surgery/head injury in the preceding 3 weeks&#xD;
&#xD;
               5. Gastrointestinal bleeding within the last month&#xD;
&#xD;
               6. Known bleeding risk&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jesper Kjærgaard, MD PhD DMSc</last_name>
    <phone>+45 35450969</phone>
    <email>jesper.kjaergaard.05@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lia Bang, MD PhD</last_name>
    <phone>+45 35453545</phone>
    <email>lia.evi.bang@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Copenhagen University Hospital Bispebjerg Hospital</name>
      <address>
        <city>Bispebjerg</city>
        <zip>DK2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Egstrup, MD PhD</last_name>
      <phone>+45 38 63 50 00</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Copenhagen University Hospital Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lia E Bang, MD PhD</last_name>
      <phone>+45 3545 3545</phone>
      <email>lia.evi.bang@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Copenhagen University Hospital, Herlev Gentofte Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>DK2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Søren Fanø, MD PhD</last_name>
      <phone>+45 38 68 38 68</phone>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 9, 2019</study_first_submitted>
  <study_first_submitted_qc>September 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2019</study_first_posted>
  <last_update_submitted>September 11, 2019</last_update_submitted>
  <last_update_submitted_qc>September 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Jesper Kjaergaard</investigator_full_name>
    <investigator_title>Sponsor, Primary investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Embolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Main trial database</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

